PHARMING GROUP NV (PHARM.AS) Fundamental Analysis & Valuation

AMS:PHARM • NL0010391025

Current stock price

1.411 EUR
-0.01 (-0.42%)
Last:

This PHARM.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHARM.AS Profitability Analysis

1.1 Basic Checks

  • PHARM had negative earnings in the past year.
  • In the past year PHARM had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PHARM reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: PHARM reported negative operating cash flow in multiple years.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.57%, PHARM is in the better half of the industry, outperforming 68.06% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 1.03%, PHARM is in the better half of the industry, outperforming 73.61% of the companies in the same industry.
  • The Return On Invested Capital of PHARM (7.06%) is better than 79.17% of its industry peers.
Industry RankSector Rank
ROA 0.57%
ROE 1.03%
ROIC 7.06%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.76%, PHARM is in the better half of the industry, outperforming 69.44% of the companies in the same industry.
  • PHARM's Profit Margin has declined in the last couple of years.
  • With a decent Operating Margin value of 9.61%, PHARM is doing good in the industry, outperforming 77.78% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PHARM has declined.
  • PHARM's Gross Margin of 87.90% is amongst the best of the industry. PHARM outperforms 84.72% of its industry peers.
  • In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
Industry RankSector Rank
OM 9.61%
PM (TTM) 0.76%
GM 87.9%
OM growth 3Y19.98%
OM growth 5Y-24.69%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PHARM.AS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHARM is destroying value.
  • PHARM has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PHARM has been increased compared to 5 years ago.
  • Compared to 1 year ago, PHARM has an improved debt to assets ratio.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 3.89 indicates that PHARM is not in any danger for bankruptcy at the moment.
  • PHARM has a better Altman-Z score (3.89) than 66.67% of its industry peers.
  • PHARM has a debt to FCF ratio of 2.15. This is a good value and a sign of high solvency as PHARM would need 2.15 years to pay back of all of its debts.
  • The Debt to FCF ratio of PHARM (2.15) is better than 88.89% of its industry peers.
  • A Debt/Equity ratio of 0.39 indicates that PHARM is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.39, PHARM perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Altman-Z 3.89
ROIC/WACC1
WACC7.09%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 2.59 indicates that PHARM has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.59, PHARM is in line with its industry, outperforming 55.56% of the companies in the same industry.
  • PHARM has a Quick Ratio of 2.03. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • PHARM's Quick ratio of 2.03 is in line compared to the rest of the industry. PHARM outperforms 51.39% of its industry peers.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.03
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. PHARM.AS Growth Analysis

3.1 Past

  • PHARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 111.11%, which is quite impressive.
  • PHARM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.41% yearly.
  • Looking at the last year, PHARM shows a very strong growth in Revenue. The Revenue has grown by 26.56%.
  • PHARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.13% yearly.
EPS 1Y (TTM)111.11%
EPS 3Y-41.82%
EPS 5Y-48.41%
EPS Q2Q%60%
Revenue 1Y (TTM)26.56%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%

3.2 Future

  • The Earnings Per Share is expected to grow by 157.07% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 16.27% on average over the next years. This is quite good.
EPS Next Y1671.6%
EPS Next 2Y376.03%
EPS Next 3Y187.89%
EPS Next 5Y157.07%
Revenue Next Year8.86%
Revenue Next 2Y5.64%
Revenue Next 3Y0.12%
Revenue Next 5Y16.27%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. PHARM.AS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Forward Earnings ratio of 46.51, the valuation of PHARM can be described as expensive.
  • 77.78% of the companies in the same industry are more expensive than PHARM, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of PHARM to the average of the S&P500 Index (21.99), we can say PHARM is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 46.51
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHARM indicates a somewhat cheap valuation: PHARM is cheaper than 75.00% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, PHARM is valued cheaper than 84.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.57
EV/EBITDA 22.63
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • PHARM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PHARM's earnings are expected to grow with 187.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y376.03%
EPS Next 3Y187.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHARM.AS Dividend Analysis

5.1 Amount

  • PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARM.AS Fundamentals: All Metrics, Ratios and Statistics

PHARMING GROUP NV

AMS:PHARM (4/29/2026, 3:29:38 PM)

1.411

-0.01 (-0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength40.54
Industry Growth78
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners21.67%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap996.52M
Revenue(TTM)376.13M
Net Income(TTM)2.85M
Analysts88.57
Price Target2.26 (60.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)532.06%
Min EPS beat(2)-6.76%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)286.26%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)81.54%
EPS beat(12)5
Avg EPS beat(12)48.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.68%
Max Revenue beat(2)1.11%
Revenue beat(4)3
Avg Revenue beat(4)5.37%
Min Revenue beat(4)-1.68%
Max Revenue beat(4)13.37%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)7
Avg Revenue beat(12)0.29%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.91%
PT rev (3m)4.86%
EPS NQ rev (1m)333.33%
EPS NQ rev (3m)-78.33%
EPS NY rev (1m)-10.42%
EPS NY rev (3m)35.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 46.51
P/S 3.09
P/FCF 21.57
P/OCF 21.28
P/B 4.2
P/tB 8.22
EV/EBITDA 22.63
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY2.15%
FCF(TTM)0.07
FCFY4.64%
OCF(TTM)0.07
OCFY4.7%
SpS0.46
BVpS0.34
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 0.57%
ROE 1.03%
ROCE 9.41%
ROIC 7.06%
ROICexc 13.22%
ROICexgc 38.98%
OM 9.61%
PM (TTM) 0.76%
GM 87.9%
FCFM 14.34%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y56.06%
ROICexgc growth 5Y-23.52%
ROICexc growth 3Y34.74%
ROICexc growth 5Y-22.16%
OM growth 3Y19.98%
OM growth 5Y-24.69%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Debt/EBITDA 2.26
Cap/Depr 6.73%
Cap/Sales 0.2%
Interest Coverage 5.83
Cash Conversion 115.52%
Profit Quality 1892.42%
Current Ratio 2.59
Quick Ratio 2.03
Altman-Z 3.89
F-Score6
WACC7.09%
ROIC/WACC1
Cap/Depr(3y)6.96%
Cap/Depr(5y)24.22%
Cap/Sales(3y)0.36%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3Y-41.82%
EPS 5Y-48.41%
EPS Q2Q%60%
EPS Next Y1671.6%
EPS Next 2Y376.03%
EPS Next 3Y187.89%
EPS Next 5Y157.07%
Revenue 1Y (TTM)26.56%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%
Revenue Next Year8.86%
Revenue Next 2Y5.64%
Revenue Next 3Y0.12%
Revenue Next 5Y16.27%
EBIT growth 1Y519.14%
EBIT growth 3Y46.74%
EBIT growth 5Y-15.55%
EBIT Next Year4.35%
EBIT Next 3Y34.62%
EBIT Next 5Y57.73%
FCF growth 1Y2182.32%
FCF growth 3Y38.11%
FCF growth 5Y-4.61%
OCF growth 1Y3147.8%
OCF growth 3Y34.55%
OCF growth 5Y-8.14%

PHARMING GROUP NV / PHARM.AS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PHARM.AS.


What is the valuation status for PHARM stock?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.


What is the profitability of PHARM stock?

PHARMING GROUP NV (PHARM.AS) has a profitability rating of 4 / 10.


What is the financial health of PHARMING GROUP NV (PHARM.AS) stock?

The financial health rating of PHARMING GROUP NV (PHARM.AS) is 7 / 10.